StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

571 Study Matches

A PHASE 2, MULTICENTER, PLACEBO-CONTROLLED,RANDOMIZED, DOUBLE-BLIND, 48-WEEK STUDY TOEVALUATE THE EFFICACY AND SAFETY OF COMBINATIONTHERAPY OF K-877-ER AND CSG452 IN PATIENTS WITHNONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH)WITH LIVER FIBROSIS

This is a Phase 2, multicenter, double-blind, randomized, 52-week study to assess the efficacy and safety of K-001 medication compared with placebo in subjects with noncirrhotic NASH with liver fibrosis. This study will look at a study drug, called K-001, for participants with a liver condition called noncirrhotic nonalcoholic steatohepatitis (NASH). This condition is defined by a build-up of fat in the liver, which causes liver damage and inflammation. Due to this damage, the liver does not work as well. If left untreated, NASH can lead to liver fibrosis (scarring of the liver), liver cancer, or liver failure. K-001 is a once daily pill that contains combination of two medicines: K-877-ER and CSG452. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with NASH with liver fibrosis. To answer these questions, the study drug will be compared with a placebo.

There will be 10 in person visits over 52-week study period. Various procedures will be completed such as a fibroscan, ECG, liver MRI, liver biopsy, blood draws. You will be randomly assigned by chance (like the flip of a coin) to receive the study drugs or placebo (inactive substance). You will be taking a pill once daily.

$1310

Yes
 

Jonathan Stine
Nataliya Smith - at nsmith9@pennstatehealth.psu.edu or 717-531-0003, ext=320223
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05327127
STUDY00023757
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥18 years
NASH diagnosis
Stage 1, 2 or 3 fibrosis

Exclusion Criteria:
Causes of liver disease other than NAFLD
Chronic alcohol or drug abuse
Cirrhosis
History of liver transplant, or subjects listed for liver transplantation
Inability to provide informed consent
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Understanding healthcare workers perception and knowledge of dysphagia

The purpose of this study is to gain a greater understanding of healthcare workers’ knowledge of and perception of dysphagia in older adults. Study participants will fill out a survey/questionnaire in a single study session. This is expected to take 15-20 minutes.

You will be asked to complete a single, brief survey. It will take no more than 15-20 minutes.

No
 

Aarthi Madhavan
Aarthi Madhavan - at aarthi@psu.edu
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT00000000
STUDY00024236
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 and older
Active healthcare workers or care providers for community dwelling older adults over 60 years old
Working with older adults
English proficiency at 8th grade level

Exclusion Criteria:
Never worked with older adults
Not working clinically currently
Diagnosed mild cognitive impairment or dementia
Infectious Diseases & Immune System, Food & Nutrition, Prevention
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov

Understanding University Students' Daily Interaction with ChatGPT through the Lens of Self-Determination Theory

This study aims to learn about how university students interact with ChatGPT and how ChatGPT's support of autonomy, competence, and relatedness could either help or hinder students' ability to learn. We will interview students to understand how ChatGPT supports student learning and identify any challenges that may arise.

There will be a 60-minute interview.

$10

No
 

Jiyoon Kim
jxk6167@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024072
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Students
Use ChatGPT for their daily lives
Over 18 years old
Speak English
Students from non-EU countries

Exclusion Criteria:
Non-students
Under 18 years old
Do not use ChatGPT for their daily lives
Non-english speaker
Students from EU countries
Education
I'm interested
Share via email

Identifying an Alternative to the Classic Presentation of Autism: The ISM Autism Presentation

This study aims to build upon a previous study that established a different presentation of autism called the ISM presentation by using a large sample size to either confirm or dispute this presentation as an alternative to classical autism.

Participants will be required to complete a survey expected to take no longer than an hour.

No
 

Zak Kabbara
Zouheir Kabbara - at zak5195@psu.edu or 478-737-4600
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024256
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Reside in the USA
At least 18 years old
Either diagnosed with autism, suspected of having autism or typically developing

Exclusion Criteria:
Is unable to read independently or complete the survey
I'm interested
Share via email

Towards Efficient Adaptive Federated Learning: Algorithms, Theories, and Applications

The broad goal of this project is to provide both theoretical and algorithmic solutions for efficient adaptive federated learning, as well as build practical adaptive federated learning systems for real-world applications.

Each participant carrying or wearing a smart device will conduct six activities, including (a) Wiping the whiteboard; (b) Walking; (c) Moving a suitcase; (d) Rotating the chair; (e) Sitting; (f) Standing up and sitting down. We will collect nine signals from each smart device, including three axes of the accelerometer, three axes of the gyroscope, and three axes of the magnetometer.

$20

Yes
 

Jinghui Chen
Jinghui Chen - at jzc5917@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024201
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
The proposed study will involve adults no less than 18 years old.
Efforts will be made to include both men and women.
No Vulnerable populations will be included.

Exclusion Criteria:
Vulnerable populations such as pregnant women, children, cognitive impaired adults, and prisoners.
People who are less than 18 years old.
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Understanding the Relationship Between Discrimination and Sickle Cell Pain

This is a survey and interview study recruiting patients with sickle cell disease (SCD). Participants will answer questionnaires and complete a remote interview about health care experiences, pain, and discrimination. Natural language processing of interview transcripts will be used to quantify linguistic features indicative of subjective associations between individual experiences of racial discrimination and sickle cell pain.

Participants will be asked to fill out questionnaires and answer questions during an interview.

$50

No
 

Elizabeth Losin
Jacob Gronemeyer - at jgronemeyer@psu.edu
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00023905
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of Sickle Cell Disease
18 years or older

Exclusion Criteria:
Under the age of 18
Does not have a confirmed diagnosis of Sickle Cell Disease
Unable or unwilling to participate in the interview or to be recorded
Not Fluent in the English langauge
Blood Disorders, Pain Management
Not applicable
I'm interested
Share via email

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome

Participants 18 years and older who meet the diagnostic criteria for the basal cell nevus (Gorlin) syndrome will be assigned to receive either Patidegib Gel 2% or Placebo (no active medicine) to apply twice daily for 12 months. The assignment will be made according to sex assigned at birth, age, and number of BCC lesions at the treatment area at Baseline. The primary endpoint is a comparison between the 2 treatment arms of the number of new BCCs at Month 12 compared to Baseline. The BCCs will be imaged and tracked consistently throughout the study to identify new BCCs and to confirm their diagnosis by dermoscopy (handheld instrument with a 15x magnification lens and a cross-polarized light source).

Participants will participate in 15 visits over approximately 14 months (attend 6 in person visits along with 9 phone call visits). In addition, participants will receive study medication to apply twice a day for 12 months and undergo clinical tests at various time points, which include blood tests, ECG, complete questionnaires/diary, skin exam and skin photographs.

Compensation is provided for eligible participants.

Yes
 

Elizabeth Billingsley
Samantha Gettle - at dermatologyclinicaltrials@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06050122
STUDY00023809
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be confirmed to have a PTCH1 mutation
Diagnostic criteria present for Gorlin Syndrome
10 BCCs present on face at Randomization (Baseline/Day 1)

Exclusion Criteria:
Certain medications are not allowed during study; study coordinator will discuss
uncontrolled systemic disease
uncontrolled skin disease on the face.
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial

This study will examine whether patients who have insomnia with different sleep characteristics demonstrate a differential response to two common insomnia treatments, Cognitive Behavioral Therapy for Insomnia (CBT-I) and trazodone. All participants will complete a trial of CBT-I, followed by a medication trial in some participants. Participants will be evaluated with structured interviews; self-report questionnaires; in lab sleep recording; activity monitoring; saliva, blood, & urine collection for routine clinical measures; blood pressure monitoring and an EKG. All outcomes will be assessed again following the end of treatment.

Study involvement is 9-12 monthsPhone Screen to determine basic eligibility.There are 5-6 in person visits (first is consent/screening visit)3-4 of the in person visits are overnight visits to the sleep labUp to 18 other visits for treatment may be done in person or by video conference.Data is collected at home for 6-8 weeks during the 12 month period (activity monitor & blood pressure)Online self-completed surveys & structured interviews are required.A single blood sample and saliva samples will be collectedPregnancy Test, 12-Lead EKG, Medication may need to be taken in addition to the CBT-I Sessions

$465.00

Yes
 

Alexandros Vgontzas
Carrie Criley - at SONOSleep@pennstatehealth.psu.edu or 717-531-4123
Psychiatry and Behavioral Health (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06281756
STUDY00022285
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Chronic Insomnia more than 3 months
Elevated or High Blood Pressure with or without treatment
Body Mass Index <40

Exclusion Criteria:
Pregnant/Breastfeeding
Unstable Medical Condition
Severe Sleep Apnea
Substance Abuse
Severe Mental Illness (ie, psychosis)
Sleep Management
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Exercise pressor reflex in peripheral artery disease patients with leg revascularization

The purpose of this research study is to better understand how leg blood flow is regulated in healthy people and patients with Peripheral Arterial Disease (PAD). It is also being done to examine if a standard-of-care peripheral intervention procedure to improve blood flow to the leg in PAD patients will improve the oxygen delivery and blood flow response to exercise in their legs.

Healthy subjects will participate in 1 visit and perform handgrip and foot (plantar flexion) exercises while several non-invasive measurements are recorded.

You will receive $25 per hour for your participation in this research study

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023729
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women at least 21 years of age
All races and ethnicities welcome
Can speak and understand spoken English
Healthy status as defined by history and physical
Females may be on oral contraceptives, but will be excluded if they are pregnant or lactating

Exclusion Criteria:
less than 21 years of age
Pregnant or nursing women
Have a major disease (heart, lungs, kidney, diabetes, cancer)
Have resting blood pressure of 150/100 or higher
current smoker
Heart & Vascular
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 23-121 Phase III Randomized Trial of Stereotactic ablativeradiotherapy (SAbR) for Oligometastatic Advanced RenalCarcinoma (SOAR)

This study is looking at patients with oligometastasis comparing chemotherapy and SABR with chemotherapy alone

•Blood counts and blood chemistry done at initiation and every three months to make sure you are not having any side effects from the study affecting your blood counts.•CT or MRI scans done at initiation and every three months to monitor the response of the treatment to your cancer•Physical exams done every three months to confirm your general well-being and to detect side effects from the study.Compete physical and well being form as set below:•Baseline•3 months from start of treatment•6 months from start of treatment•9 months from start of treatment•12 months from start of treatment•18 months from start of treatment•24 months from start of treatment

Yes
 

Stuthi Perimbeti
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05863351
STUDY00023912
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
must be 18 or older
patient may not have brain metastases
Patient may have any RCC histology except a histology that has a sarcomatoid component.
Patient must have a pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma (RCC) prior to randomization.
Patient must have primary site addressed by local therapy. If the primary RCC is intact, the patient must undergo local treatment to the primary before randomization.

Exclusion Criteria:
Patient must not have received any prior systemic therapy (except for adjuvant setting, see 3.1.9) for metastatic RCC.
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used
Patients must not expect to conceive until after 6 months after the last dose of protocol medication
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
In order to participate in the QOL portion of the protocol, the patient must speak English or Spanish.
Kidney & Urinary System, Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Non-Hispanic Black Individuals and Vascular Function

This study will examine the impact of age, sex, and racial/ethnic background on vascular function.

There will be three in-person visits: one screening, one experimental visit, and one visit to return equipment (if applicable). Blood will be drawn at the screening and experimental visit. Participants will undergo tests for cardiovascular measures.

$100

Yes
 

Lacy Alexander
Virginia Content - at vgc5042@psu.edu or 814-863-2140
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023545
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-75 years of age
Male or Female
Identify as Non-Hispanic Black or Non-Hispanic White

Exclusion Criteria:
Tobacco consumption (e.g., smoking)
Recreational drug use (e.g., marijuana)
Pregnant and/or breastfeeding
Taking blood pressure medication
Diagnosed with metabolic and/or cardiovascular disease(s)
Heart & Vascular
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants with Idiopathic Pulmonary Fibrosis

This is a phase 2 pharmaceutical sponsored clinical trial looking to evaluate the safety, tolerability, and efficacy of experimental drug TTI-101 in patients with Idiopathic Pulmonary Fibrosis (IPF).

Participants will attend 7 visits over 18-20 weeks at the Penn State Hershey Medical Center. Participants will receive study treatment for 12 weeks and the study doctor will continue to monitor you for 4 weeks. The study visits will involve completing some procedures and tests such as taking some blood and urine samples, taking vitals signs, physical exams, electrocardiograms (ECGs), questionnaires, breathing and walking tests, and a high-resolution computed tomography (HRCT) scan.

1050

Yes
 

Rebecca Bascom
Tim Sheehan - at tsheehan@pennstatehealth.psu.edu or 717-531-2925
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05671835
STUDY00023129
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
>/= 40 years of age
Diagnosis of Idiopathic Pulmonary Fibrosis
Able to perform breathing tests

Exclusion Criteria:
Received pirfenidone in last 3 months
Receiving steroids >10mg/day
Other types of respiratory disease
Other uncontrolled, clinically relevant disease
No active cancer
Lung Disease & Asthma
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Music Appreciation of Pediatric and Adult Hearing Aid Users over Time

The purpose of this study is to survey hearing aid users over a 6 month time period to see if their music perception improves over time.

Study participants will complete surveys about their music experience four times: first at your initial clinic visit and then sent to your email at 1, 3, and 6 months following your visit. This survey will include questions about the participants experience with music as well as name, age, gender, and duration of hearing aid use.

Yes
 

Varun Patel
Caia Hypatia - at chypatia@pennstatehealth.psu.edu
Otolaryngology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
STUDY00023837
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Acquired hearing loss
Hearing aid use

Exclusion Criteria:
Cochlear implant use
Auditory implants including bone anchored hearing aids
Poor compliance with the use of hearing aids
Age 12 years old or younger
Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Errorless and error-based syntactic priming effects in neurologically intact older adults

This research study is being done to understand how different techniques for practicing sentences are affected by healthy aging. This will help us create better language therapy for people with aphasia.

There will be one visit. It can be in-person or over Zoom. We will ask you to fill out a questionnaire about yourself, complete a brief cognitive assessment, and complete a sentence production task. This visit should only last about 90 minutes.

up to $15

No
 

Chaleece Sandberg
Parisa Osfoori - at pvo5112@psu.edu
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024639
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
at least 40 years of age
native speaker of English
at least high school education
normal or corrected-to-normal vision and hearing

Exclusion Criteria:
history of neurodegenerative disorder (e.g., Alzheimer's)
history of acquired neurological disorder (e.g., stroke)
history of developmental neurological disorder (e.g., dyslexia, autism)
history of psychiatric disorder (e.g., schizophrenia)
active medical condition (e.g. cancer) or medications that could affect cognition (e.g., opiods)
Language & Linguistics
I'm interested
Share via email

The naturalistic reinforcement of obsessions and compulsions: An ecological momentary assessment study

The purpose of this study is to examine the relationship between sleep patterns, thoughts, behaviors, and emotions in obsessive-compulsive disorder (OCD). In the screening visit, participants will complete a brief interview and questionnaire to determine if they are eligible to participate in our study. Eligible participants will complete additional questionnaires and a training session on study procedures. Following this visit, for the next 7 days, participants will complete daily questionnaires and monitor their sleep by wearing a sleep watch. On day 4, participants will attend a brief compliance check Zoom visit where they will be informed about their overall compliance rate. Participants will be compensated with either course credit or an Amazon e-giftcard. Findings from this research may help improve understanding of OCD symptoms and sleep.

Screening Visit: This can be conducted in person or over Zoom. During this visit, we will administer a short questionnaire and an interview to determine if you are eligible to participate in the study. If you are eligible, you will complete questionnaires and a training session on study procedures. You will also receive a sleep watch, which you will be asked to wear consequently for 7 days. This visit will take approximately 1 hour and 25 minutes.7 Day Monitoring: For the next 7 days, you will complete several, brief daily questionnaires (7 questionnaires/per day) on your smartphone. Questionnaires will take place generally every 2 hours starting from 10 a.m. to 10 p.m. You will also monitor your sleep by wearing a sleep watch and maintaining a daily sleep diary.Compliance Check (Day 4): On day 4, there will be a 5 minute compliance check Zoom meeting where you will be informed about your overall study compliance rate. Return and Debrief: At the end of the 7 days, you will be asked to return the sleep watch to our lab location (Moore Building) or schedule a pick-up time with a study team member. You will also receive an educational debriefing handout over email.

$50

No
 

Valerie Swisher
Valerie Swisher - at vss5199@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00024470
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Meets criteria for Obsessive-Compulsive Disorder
Owns an iPhone or Android Smartphone
Fluency in English
Age 18 or older

Exclusion Criteria:
Younger than 18
Not able to consent or commit to study duration
Does not meet criteria for Obsessive-Compulsive Disorder
Meets criteria for certain conditions (e.g., schizophrenia)
Not fluent in English
Sleep Management, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

Emotion Regulation During the Transition to Parenthood

The purpose of this study is to understand parents' experiences of emotion regulation in parenting and coparenting contexts and how individual differences in parents' emotion regulation are associated with well-being and relationship functioning.

Coparents will be asked to fill out questionnaires and engage in interviews with the researchers during three online sessions across the transition to parenthood.

110

No
 

Katherine Haigler
Katherine Haigler - at klh6263@psu.edu or 617-817-5218
Human Development and Family Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024563
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
You and your coparent are willing to participate
One parent is pregnant and in their third trimester
First-time parents
English-speaking

Exclusion Criteria:
Experiencing a psychotic episode
Pregnancy & Infertility, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

AYA-CONNECT: A qualitative study to inform creation of a social network-based peer intervention for adolescent/young adult cancer survivors

In this study, we will conduct focus groups of adolescent/young adult cancer survivors (AYACS) (at least 15 total AYACS) 15-25 years old to understand their perspectives on the importance of peer connection and social connectedness during and after cancer treatment, the role of an intervention to foster peer connections, and suggestions/feedback on designing AYA-CONNECT (an AYACS-peer network intervention) including delivery format, structure, and content to promote life goals and health-related behaviors.

You will participate in one focus group that will last about 1 hour.

$20

No
 

Pooja Rao
Pooja Rao - at prao2@pennstatehealth.psu.edu
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
STUDY00024174
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participant age 15-25 years old at time of cancer diagnosis and within 5 years of initial cancer diagnosis
Participant is receiving or has received any oncologic care at Penn State Health Children’s Hospital or Penn State Cancer Institute
Participant fluency in written and spoken English for participants > 18 years old

Parent and participant fluency in written and spoken English for participants < 18 years old
Access to computer or smartphone

Exclusion Criteria:
Non-English speaking
Participants with cognitive or physical inability to participate in study
Cancer
Not applicable
I'm interested
Share via email

Nicotine absorption, toxicant exposure, and subjective effects of a heat-not burn tobacco product

The purpose of this study is to evaluate the nicotine delivery, toxicant exposure, and subjective effects associated with the use of heat-not burn tobacco products, compared with electronic cigarettes.

Participants will attend 2 clinic visits at the Penn State Milton S. Hershey Medical Center lasting approximately 1 ½ hours each. Participants will be asked to refrain from using any tobacco or nicotine products for at least 14 hours prior to each visit. During the visit participants will try the new tobacco products in the study center while blood samples are collected through an IV catheter placed in the arm.

120

Yes
 

Jonathan Foulds
Allison Salkin - at asalkin@pennstatehealth.psu.edu or 844-207-6392
Public Health Sciences (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013801
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 21-60
Current daily cigarette smoker (5 or more per day)

Exclusion Criteria:
Currently pregnant
History of a seizure disorder or had a seizure in the past 12 months
History of difficulty providing or unwilling to provide blood samples
Current user of an IQOS device
Current user of an electronic cigarette device
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Advanced fMRI Study on the Functional Abnormality of BNST in Anorexia Nervosa Restricting-type

This research is being done to better understand how certain parts of the brain may react differently in people who have a particular eating disorder, anorexia nervosa, which may help us understand why they respond to food in the way they do. This may help us design more effective treatments for people with anorexia nervosa.

You will complete a package of surveys for personality, psychopathology, an evaluation of taste functions, and an MRI/fMRI examination.

Up to a total of $100.

Yes
 

Jian-Li Wang
Nicholas Corbett - at ncorbett@pennstatehealth.psu.edu or 717-531-0003, ext=323023
Radiology (HERSHEY)
 

Female
All
This study is also accepting healthy volunteers
STUDY00021467
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 10 to 24 years-old female
Anorexia nervosa restricting type patients
Healthy volunteer with normal body weight
Right-handed
Fluent in written and spoken English

Exclusion Criteria:
Left-handed
Pregnancy or breastfeeding
History of diabetes, substance abuse, head trauma
Allergy to milk and milk products
Cannot have MRI due to claustrophobia or specific implants
Children's Health, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON)

This is a phase 2b clinical trial looking to see if the drug PLN-74809 (bexotegrast) is effective and safe in patients diagnosed with idiopathic pulmonary fibrosis (IPF).

If you choose to participate in this study and meet all the study entry requirements, you will be randomly assigned (by chance; like the flip of a coin) to receive either bexotegrast or placebo for the whole study. Neither your study doctor nor you will know whether you are receiving bexotegrast or placebo. You will be required to visit the Hershey Medical Center on at least 8 separate occasions over an approximate 58-week period. Procedures that will be performed during your visits include, but are not limited to, physical exams, blood tests, ECGs, completing questionnaires, lung functions tests, and CT scans.

1200

Yes
 

Rebecca Bascom
Timothy Sheehan - at tsheehan@pennstatehealth.psu.edu or 717-531-2925
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06097260
STUDY00023219
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
>/= 40 years of age
IPF diagnosis ≤ 7 years prior to screening
If on Ofev or Esbriet, must be on stable dose for >/= 12 weeks
FVC >/=45% predicted
DLCO >/= 30% predicted and </= 90% predicted

Exclusion Criteria:
Taking medication for pulmonary hypertension
Obstructive lung disease
Current smokers
Active infection
IPF exacerbation within the last 6 months
Lung Disease & Asthma
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase 3 Randomized, Placebo-controlled, Double-blind Study toEvaluate the Efficacy and Safety of BBP-418 (ribitol) in Patients withLimb Girdle Muscular Dystrophy 2I (LGMD2I)

This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with Limb Girdle Muscular Dystrophy.

You will receive study drug (BBP-418) two times per day and your dose will depend on how much you weigh. You will be provided with study drug to be used for dosing at home along with a paper study drug diary and instructions for completing it. You will be expected to return all used and unused study drug packets and a paper study drug diary as instructed by the site staff.Study visits will include: blood and urine samples, blood samples overtime (within 1 hour before dosing, 1 hour after dosing and 4 hours after dosing), ECHO, EKG, muscle biopsies (3 for adults, 2 children), Spirometry (tests how well you breathe in and out), 10 meter walk test, 100 meter walk test, additional tests to see how you move while lying down, standing and walking, tests for your arms and hands while in a chair

$1950.00

Yes
 

Mansoureh Mamarabadi
nervemuscle@pennstatehealth.psu.edu 717-531-8257
Neurology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05775848
STUDY00022349
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have a genetically confirmed diagnosis of LGMD2I/R9
Male or female participants 12 to 60 years of age (inclusive)
Have a body weight >30 kg
Female participants of childbearing potential and male participants of reproductive potential must be willing to use a highly effective method of contraception from time of consent through 12 weeks after last dose
Willing and able to complete all study procedures, including biopsies, according to the Schedule of Assessments

Exclusion Criteria:
If pregnant and/or breastfeeding or planning to conceive children within the projected duration of the study through 12 weeks after the last dose of study treatment
Use of ribose or other sugar alcohol-containing supplement within 90 days of the Screening Visit
Use of a systemic corticosteroid for the treatment of muscular dystrophy within 90 days of the Screening Visit.
Previously received gene therapy to treat LGMD2I/R9
Presence of a platelet disorder, bleeding disorder, or other contraindication to muscle biopsy
Neurology
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 23-144 NRG-LU008: PHASE III PROSPECTIVE RANDOMIZED TRIAL OF PRIMARY LUNG TUMOR STEREOTACTIC BODY RADIATION THERAPYFOLLOWED BY CONCURRENT MEDIASTINAL CHEMORADIATION FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER

Patients diagnosed withy inoperable node positive non small cell lung cancer will be randomized to with radiation therapy to all know sites of disease in the lung, followed by immunotherapy or radiation to the primary lung tumor, followed by radiation to the lymph nodes followed by immunotherapy

Participants will be required to come to all study visits, report to the study doctor any new medications, prescription or over the counter that they may be taking,

Yes
 

Joseph Miccio
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Radiation Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05624996
STUDY00024448
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of Stage II or III (AJCC Eighth Edition) non-small cell lung cancer (NSCLC) with known PD-L1 status prior to registration.
The patient must be deemed clinically appropriate for curative intent definitive combined modality therapy, based on the following staging assessments:
No evidence of distant metastases based on FDG PET/CT scan obtainedwithin 60 days of registration.
Primary tumor ≤ 7 cm;
Age ≥ 18;

Exclusion Criteria:
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields that is determined by the treating physician to impede the treatment of the study malignancy.
Patients without identifiable primary tumor
Centrally located primary tumor < 2 cm from involved nodal disease which would result in significant overlap of the primary SBRT and nodal radiation fields
Participants who are pregnant or unwilling to discontinue nursing.
Participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) unwilling to use highly effective contraceptives during therapy
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 23-145 Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

This trial is comparing two different therapies for the treatment of newly diagnosed multiple myeloma who are not having a bone marrow transplant.

Subjects will be required to keep all research visits, take medications as directed, report any new medication of side effects to the study team,

Yes
 

Kevin Rakszawski
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04566328
STUDY00024221
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must have suspected or confirmed newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria and must not have received more than one cycle of treatment.
Patient must be considered ineligible for autologous stem cell transplantation by the treating physician, or willing to delay stem cell transplantion until first relapse or later.
Patient must agree to register to the mandatory Celgene Revlimid REMS program and be willing and able to comply with the requirements of the Revlimid REMS program.
Patient must have standard risk MM as defined by the Revised International Staging System (R-ISS) Stage I or II.31
Patient must be able to undergo diagnostic bone marrow aspirate following preregistration if not performed previously.

Exclusion Criteria:
Patient must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
Patient must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
Patient must not have moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.
Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation.
Patient must not have peripheral neuropathy ≥ Grade 2 on clinical examination or grade 1 with pain
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 3 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,
Reading, PA ,

Investigating the effect of restaurant environment on food intake using mixed reality application.

This study investigates the influence of different rest design of restaurant on participants’ food consumption behavior. More specifically, visually pleasant versus visually unpleasant design elements are included in two cafe settings to study their influence on participant liking, and emotion response. To accomplish this, we will conduct an experiment where participants will be eating a meal while immersed in a virtual café interior with two different designs using a VR headset. Their food intake will be measured.

Participants will visit the lab for 3 sessions to eat a meal each time while wearing an immersive virtual reality headset.

$30

Yes
 

Travis Masterson
Keerthana Govindarazan - at kmg6763@psu.edu
Nutritional Sciences (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT00000000
STUDY00024330
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between the ages of 18-65
Fluent in English
Free of self-reported food allergies
No diagnosis of cognitive or physical disabilities that may affect appetite or eating behaviors
No diagnosis of disabilities that may affect sensory proprioception related to virtual reality

Exclusion Criteria:
Are younger than 18 or older than 65 years of age
Not fluent in English
Have self-reported food allergies
Have a diagnosis of cognitive or physical disabilities that may affect appetite or eating behaviors
Have a diagnosis of disabilities that may affect sensory proprioception related to virtual reality
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

SPICE UP MyPlate - Strategy for Promoting Intake of Delicious Healthful Dietary Patterns Based on MyPlate: A Pilot Study

The aim is to conduct a pilot study to assess the feasibility, acceptability and potential effectiveness of culinary focused nutrition education to promote increased adherence to the Dietary Guidelines for Americans compared to standard low-intensity care.

You will be asked to attend two fasting clinic visits. At these visits paperwork will be completed, measures of weight, height, waist circumference, and vascular health will be taken. A blood draw will also be taken. If you are randomized to the culinary focused nutrition education group, you will be asked to attend weekly 1-hour face-to-face group education sessions during the first month of the study. For months 2 and 3 face-to-face sessions will be held bi-weekly for 1 hour. You will also receive emails containing videos and other resources. If you are in the standard nutrition education group, you will receive nutrition education via written study material and a phone application (app) and you will not have to attend education visits.

250

Yes
 

Kristina Petersen
Kayla Tate - at DCHLab@psu.edu
Nutritional Sciences (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022406
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 31-59
Involved in meal cooking at home and consumes a home cooked meal ≥ 1 time per week
Non-smoking

Exclusion Criteria:
A member of the household is already enrolled
Received nutrition education for a medical condition within the past 6 months
Currently following a weight loss diet
Lost ≥ 10% body weight in the past 6 months
Unstable medical conditions requiring active intervention
Food & Nutrition
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Enhancing lives: CBG, neurocircuits, and CIPN breakthroughs.

The primary aim of this research is to investigate the neural activity patterns and functional connections within brain regions associated with pain perception in individuals suffering from Chemotherapy-Induced Peripheral Neuropathy (CIPN). Specifically, the study aims to explore how the use or abstention from minor cannabinoids affects these patterns. Prior research has demonstrated that central sensitization, a process that enhances neuronal excitability and synaptic effectiveness in the central pain pathways, plays a crucial role in the development of chronic pain conditions. However, the impact of minor cannabinoids on central sensitization in CIPN patients remains relatively uncharted.This research hypothesis posits that CIPN patients who use minor cannabinoids will exhibit reduced pain processing and altered connectivity between specific brain regions, such as the thalamus and somatosensory cortices. This study holds significant clinical relevance for multiple reasons. Firstly, if minor cannabinoids are found to mitigate central sensitization, it could lead to more effective pain management for CIPN patients, ultimately improving their overall quality of life. Secondly, it may reduce the reliance on opioids for pain control, thereby contributing to the broader efforts to combat the opioid crisis. Lastly, by preventing the development of chronic pain during chemotherapy, it can enhance the overall care provided by healthcare professionals.

1.This study will be done using a MRI. 2. There is one visit to Hershey Medical Center. The time to complete the study will be 1 to 2 hours.3. Heat and Cold probes will be on your right foot and right thigh.4. The MRI is being used to see how the brain responds to the heat and cold.

$50

Yes
 

Nicholas Graziane
Nicholas Graziane - at ngraziane@pennstatehealth.psu.edu or 717-531-0003, ext=329159
Anesthesiology and Perioperative Medicine (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023760
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of CIPN or healthy controls
Minor cannabinoid use (CBD, CBG, cannabinoid oils) or not using cannabinoids
Willingness to participate
Stable medication regimen
Ability to provide consent

Exclusion Criteria:
current substance use disorder (self-report)
CNS disorders
known allergies (ragweed, pollen, ect.)
severe psychiatric disorders
pregnancy or breastfeeding
Men's Health, Cancer, Women's Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Effects of Vitamin B6 on the Exercise Pressor Reflex in Lower Limb Ischemia-Reperfusion

In this study, we are trying to determine whether Vitamin B6 will help improve the exercise-induced cardiovascular response in healthy participants following a procedure by restricting and recovering the blood flow to the leg.

There will be 6 in-person visits over a month long supplementation of Vitamin B6. Three visits will include a blood draw. Half of the visits will include walking a treadmill and 3 will involve foot exercise (plantar flexion)

You will receive $25/hour for in-person visits and $50 for completing the B6 supplementation

Yes
 

Lu Qin
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT06369350
STUDY00020217
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Males or females at least 21 - 70 years of age
All races and ethnicities welcome
Can speak and understand spoken English
Healthy status as defined by history and physical
Females may be on oral contraceptives, but will be excluded if they are pregnant or lactating

Exclusion Criteria:
Pregnant or nursing woman
Current smoker
Known allergy or hypersensitivity to Vitamin B6
Use of recreational drugs in the past 6 months
Taking any medication containing B6 (including multivitamins)
Heart & Vascular
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Oxidative Stress and Harmful Constituent Levels Associated with Little Cigars

The propose of this voluntary research study is to look at the effect of little cigars on biomarkers of potential harm with a focus on oxidative stress and inflammation. The study is also interested the effect of flavors in little cigar.

Subjects will attend 7 study visits over 7 weeks. They will be sent home with a selection of little cigars to use during the first week. Starting at week 2, they will be asked to smoke a certain cigar each week for the next 6 weeks at their study visit. They will be asked to answer a series of questionnaires and to provide biosamples (Exhaled Carbon Monoxide, Exhaled Breath Condensate and Spirometry).

600

Yes
 

Joshua Muscat
smokingresearch@pennstatehealth.psu.edu
Public Health Sciences (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06310187
STUDY00023967
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 21-65
Daily tobacco smoker
No serious quit attempts in previous 30 days

Exclusion Criteria:
Pregant or trying to become pregnant
Respiratory diseases
Substance Abuse
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Randomised, Double-blind, Placebo-controlled, Multi-centrePhase 2b Study to Evaluate the Efficacy, Safety and Tolerability ofAZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of thePNPLA3 rs738409 148M Risk Allele

This study is a Phase 2b, 52-week randomised, double-blind, placebo-controlled, multi-centre, multinational trial comparing once monthly subcutaneous (SC) administration of AZD2693 in participants with non-cirrhotic NASH (F2-F3) who are homozygous for the PNPLA3 rs738409 148M risk allele. Over the course of the approximately year long protocol, study participants will be screened to determine whether they carry the allele, which is known to place those with the allele at an increased risk for fatty liver disease. Screening will further take place to evaluate a participant's inclusion in the study, to make sure they are an eligible candidate. This screening includes blood work, a physical, and some additional diagnostic tests. If a patient is determined eligible to be randomized, the participant will complete approximately bi-weekly visits for up to a year. These visits will include bloodwork and additional evaluations to make sure they are doing well, as they receive their injections. At the completion of the study, participants will complete a final work up to see if the treatment was safe and effective.

There will be a genetic screening for an allele of the PNPLA3 gene.There will be a further screening period to determine eligibility.There will then be up to 24 visits with up to 10 injections of the study drug or placebo. Visits will require various blood work, biopsies of the liver, ECG's, and questionnaires.

$1600

Yes
 

Jonathan Stine
stinelaboratory@pennstatehealth.psu.edu
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05809934
STUDY00023755
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants who consent to give blood and buccal swab samples for genetic testing and diagnostic test development for PNPLA3 rs738409 148M who are homozygous carriers (G / G genotype) for the PNPLA3 rs738409 148M risk allele,
Participants who accept to have one liver biopsy performed during the screening period and one at 54 weeks. of PCOS by Rotterdam criteria
Participants with histological evidence of NASH based on central pathologist evaluation of a liver biopsy obtained up to 6 months before randomisation

Exclusion Criteria:
Clinical, imaging, or histological evidence of cirrhosis
Presence of other chronic liver diseases (hepatitis B or C, autoimmune hepatitis, cholestatic liver disease, Wilsons disease, hemochromatosis, etc.).
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI# 24-014 OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

this trial is examining what happens if a less toxic therapy is given to triple negative breast cancer subjects who's tumor is completely gone after receiving pre surgery chemotherapy.

Participants will need to come to all research visits, reports any side effects of medication, if they are taking any over the counter medications.

Yes
 

Cristina Truica
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05812807
STUDY00024629
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥ 18 years
ECOG Performance Status 0-2
Triple Negative Breast Cancer
Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy must have been completed preoperatively.
An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization.

Exclusion Criteria:
No stage IV (metastatic) breast cancer
No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed.
No evidence of recurrent disease following preoperative therapy and surgery.
No known active liver disease, e.g. due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,